What is Wedbush's Forecast for ZNTL FY2024 Earnings?

Wedbush investment analysts have raised their earnings per share forecasts for Zentalis Pharmaceuticals for FY2024 in a research update released on Tuesday the 12th of November 2019. Analyst R.Driscoll is now predicting that the company will report earnings of ($ 3 ) per share for the year an increase, from their estimate of ($ 5 ). Wedbush presently has a " rating and a target price of dollars four on the shares.According to market analysts Zentalis Pharmaceuticals is expected to report a loss of around $2 for the fiscal year, per share. Wedbush has also provided predictions for Zentalis Pharmaceuticals’ earnings in the quarter of 2025 (expected to be a loss of $ ̶6̶ ̶6̶ cents per share) the first quarter of 2025 (expected to be a loss of $ ̶6̶9̶ cents per share) the second quarter of 2025 (expected to be a loss of $70 cents per share) the third quarter of 2025 (expected to be a loss of $56 cents per share) and the fourth quarter of 2025 (expected to be a loss of $57 cents per share). Additionally; they provided estimates for the full year earnings in FY2025(expected to result in a loss of $248 cents, per share) FY2026(expected to result in a decrease with$222centsper share) FY2027(expected decrease with$167centsper share) and FY2018(expected decrease with$88centspershare).

Several other brokerage firms have also published reports about ZNTLs performance in the market. Oppenheimer reaffirmed their outperform" rating and established a price target of $20 for Zentalis Pharmaceuticals on Monday last week. HC Wainwright confirmed their recommendation to "buy" the stock and proposed a target price of $20 for shares of Zentalis Pharmaceuticals on August 12th. There are five investment analysts who have given the stock a hold rating while three others have recommended buying shares, in this company. MarketBeat.coms data indicates that the stock is currently rated as "Hold " with a target price of $10.

Check out the recent analysis, on ZNT Limited.

On the opening of the stock market week Zentalis Pharmaceuticals shares began trading at $ 4.00. The companys stock price has fluctuated between a low of $ ̧ ̧ and a high of $18 throughout the year with an average value of $± for the last month and $ ̧°°, for the last six months.

Several investment firms and hedge funds have made changes to their investments in the company recently. In the quarter of the year Erste Asset Management GmbH purchased a new stake in Zentalis Pharmaceuticals worth $37k. Additionally during the period Paloma Partners Management Co also acquired a new position in Zentalis Pharmaceuticals valued at around $37k. In the second quarter Anfield Capital Management LLC obtained a new position, in Zentalis Pharmaceuticals worth approximately $40k. In the quarter of this year Aigen Investment Management LP purchased a fresh stake in Zentalis Pharmaceuticals worth around $41 000. Additionally Capstone Investment Advisors LLC invested in shares of Zentalis Pharmaceuticals during the quarter, for approximately $48 000.

Zentalis Pharmaceuticals is a company, in the stage of biopharmaceutical research that specializes in finding and creating small molecule medications for treating different types of cancer. The ZN c3 is a product candidate designed to inhibit WEE1 protein tyrosine kinase. It is being studied in clinical trials for the treatment of advanced solid tumors and blood cancers. These trials include testing it as a treatment for uterine serous carcinoma and high grade serous ovarian cancer driven by Cyclin E1. Additionally it is being evaluated in combination with therapies for ovarian cancer and osteosarcoma. The product is also being studied in combination with encorafenib and cetuximab for colorectal cancer as well as, in pancreatic cancer clinical trials.

This breaking news update was created using cutting edge narrative science technology and financial information from MarketBeat to deliver precise updates for readers benefit.The editorial team, at MarketBeat has carefully reviewed this article before releasing it for the publics consumption.If you have any queries or feedback regarding this news piece feel free to reach out to contactus at marketbeat.com.

"Before you dive into Zentalis Pharmaceuticals details there's something you should know."

MarketBeat monitors the rated and most successful research analysts in the financial industry, who share their recommended stocks with clients regularly. MarketBeat has highlighted five stocks that leading analysts are subtly suggesting their clients purchase before the wider market takes notice... And surprisingly Zentalis Pharmaceuticals is not, among them.

Currently rated as "Hold" by analysts, at Zentalis Pharmaceuticals; however ranked analysts suggest these five stocks present superior investment opportunities.